Viridian Therapeutics, Inc.\DE — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
Viridian Therapeutics entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited, effective May 22, 2026, for manufacturing of Drug Substance and Drug Product. The agreement has an initial 5-year term with automatic renewal for successive 5-year periods. Specific product details, pricing, volumes, and manufacturing sites are redacted ([***]) in the disclosed portions, limiting visibility into the financial materiality and scope of the arrangement.
Why this rating
Manufacturing partnership is ordinary for biotech; redacted financial terms prevent full assessment relative to $943M market cap. Critical details obscured.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.